Great potentials
iCo has been building its intellectual property position, both internationally and domestically, around its two active product candidates: (1) iCo-008 (Bertilimumab) and (2) the Oral Amphotericin B assets. iCo now has twelve issued patents and nine pending patent applications as it moves towards the clinic. Total invested capital to date is about $33.25 million. (1) iCo-008 (Bertilimumab) Following authorization from Israeli health authorities, Immune Pharmaceuticals initiated a Phase 2 double-blind placebo controlled study with Bertilimumab (iCo-008). On November 17, 2015, Immune Pharmaceuticals announced that the first patient had been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of Bertilimumab in Ulcerative Colitis. As of August 28, 2017, 17 subjects have been enrolled. The UC trial was expanded to Eastern Europe with completion expected in Q2 2018 based on Immunes press release dated August 28, 2017. On October 23, 2017, Immune announced that it had closed an $18 million public offering of convertible preferred stock and warrants. A significant portion of these proceeds will be used for the continued development of Bertilimumab. (2) the Oral Amphotericin B On January 23, 2017, ICO announced it had initiated multiple, pre-clinical studies with its Oral Amphotericin B program including a multi-day fasted/fed study, a 7-day dose range finding study and, importantly, a 14-day GLP toxicology study. All three studies were completed during Q1 2017 and results were reported on June 12, 2017. The results from 7-day dose range finding study revealed no toxicities of oral Amphotericin B up to 1000mg/day. A previous bridging study between different oral amphotericin B formulations, iCo-010, iCo-019 and iCo-022, demonstrated similar oral bioavailability with no significant differences noted between the formulation groups. The 14-day GLP toxicology study revealed that oral administration of Amphotericin B, at dose levels of up to 600 mg/ day once daily for 14 days, was well tolerated with no toxicologically significant histological findings (n=38 subjects). In 2017, ICO received ethics approval in Australia and following completion of its manufacturing. ICO expected to begin this clinical study at the beginning of Q1 2018 with results expected in Q2 2018. ____________________ Hopefully, we can see some news/updates from the company anytime soon. ____________________ Warning: This is ONLY my opinion based on my readings and understandings of the previous press releases/reports/presentations from the company, which may not be accurate. Of course, this is NOT any investment advice. Please do your own DD and do your investment wisely.